Log In
Print
BCIQ
Print
Print this Print this
 

Novoeight, turoctocog alfa (recombinant FVIII) (NN7008)

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionThird-generation recombinant Factor Vlll (rFVIII)
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients with hemophilia A
Regulatory Designation

U.S. - Undisclosed Review (Treat and prevent bleeding in patients with hemophilia A);
EU - Standard Review (Treat and prevent bleeding in patients with hemophilia A);
Japan - Standard Review (Treat and prevent bleeding in patients with hemophilia A);
Australia - Orphan Drug (Treat and prevent bleeding in patients with hemophilia A);
Australia - Standard Review (Treat and prevent bleeding in patients with hemophilia A);
Switzerland - Standard Review (Treat and prevent bleeding in patients with hemophilia A)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today